CCR9, an additional member of the activation-induced chemokine receptor family [8], showed a higher expression (at least 21-fold) in NGCB-DLBCL and tFL compared with controls (Figure 1, p < 0.014). This evidence concerns the gene CCR9 and diffuse large B-cell lymphoma.